Share this video  

SITC 2021 | Mechanism of action of evorpacept

Jong Chul Park, MD, Harvard Medical School, Boston, MA, discusses the mechanism of action of evorpacept; a fusion protein designed to inhibit the CD47-SIRPα pathway on myeloid cells. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.